Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S, Gatanaga H, Hayashida T, Imahashi M, Minami R, Koga M, Samukawa S, Watanabe D, Fujii T, Tateyama M, Nakamura H, Matsushita S, Yoshino Y, Endo T, Horiba M, Taniguchi T, Moro H, Igari H, Yoshida S, Teshima T, Nakajima H, Nishizawa M, Yokomaku Y, Iwatani Y, Hachiya A, Kato S, Hasegawa N, Yoshimura K, Sugiura W, Kikuchi T. Uno S, et al. Among authors: minami r. J Antimicrob Chemother. 2023 Dec 1;78(12):2859-2868. doi: 10.1093/jac/dkad319. J Antimicrob Chemother. 2023. PMID: 37856677
Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.
Gatanaga H, Ibe S, Matsuda M, Yoshida S, Asagi T, Kondo M, Sadamasu K, Tsukada H, Masakane A, Mori H, Takata N, Minami R, Tateyama M, Koike T, Itoh T, Imai M, Nagashima M, Gejyo F, Ueda M, Hamaguchi M, Kojima Y, Shirasaka T, Kimura A, Yamamoto M, Fujita J, Oka S, Sugiura W. Gatanaga H, et al. Among authors: minami r. Antiviral Res. 2007 Jul;75(1):75-82. doi: 10.1016/j.antiviral.2006.11.012. Epub 2006 Dec 14. Antiviral Res. 2007. PMID: 17194486
Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan.
Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, Koike T, Oie M, Konda M, Sadamasu K, Nagashima M, Gatanaga H, Matsuda M, Ueda M, Masakane A, Hata M, Mizogami Y, Mori H, Minami R, Okada K, Watanabe K, Shirasaka T, Oka S, Sugiura W, Kaneda T. Fujisaki S, et al. Among authors: minami r. Jpn J Infect Dis. 2007 May;60(2-3):113-7. Jpn J Infect Dis. 2007. PMID: 17515643
Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.
Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, Sadamasu K, Kondo M, Mori H, Ueda M, Tateyama M, Ueda A, Kato S, Ito T, Oie M, Takata N, Hayashida T, Nagashima M, Matsuda M, Ibe S, Ota Y, Sasaki S, Ishigatsubo Y, Tanabe Y, Koga I, Kojima Y, Yamamoto M, Fujita J, Yokomaku Y, Koike T, Shirasaka T, Oka S, Sugiura W. Hattori J, et al. Among authors: minami r. Antiviral Res. 2010 Oct;88(1):72-9. doi: 10.1016/j.antiviral.2010.07.008. Epub 2010 Aug 6. Antiviral Res. 2010. PMID: 20692295
Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.
Watanabe D, Ibe S, Uehira T, Minami R, Sasakawa A, Yajima K, Yonemoto H, Bando H, Ogawa Y, Taniguchi T, Kasai D, Nishida Y, Yamamoto M, Kaneda T, Shirasaka T. Watanabe D, et al. Among authors: minami r. BMC Infect Dis. 2011 May 24;11:146. doi: 10.1186/1471-2334-11-146. BMC Infect Dis. 2011. PMID: 21605468 Free PMC article.
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S; Epzicom-Truvada study team. Nishijima T, et al. Intern Med. 2013;52(7):735-44. doi: 10.2169/internalmedicine.52.9155. Epub 2013 Apr 1. Intern Med. 2013. PMID: 23545667 Free article. Clinical Trial.
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team. Nishijima T, et al. PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. eCollection 2013. PLoS One. 2013. PMID: 23951362 Free PMC article. Clinical Trial.
350 results